JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment
Bio Pharma Dive
JANUARY 11, 2022
Pharma executives fielded many questions about their dealmaking intentions on the conference's second day, while Roche outlined its plan to compete against Merck and Bristol Myers in cancer immunotherapy.
Let's personalize your content